Cerebrovascular accident prophylaxis

4 trials MedDRA PT
4 Registered trials
0 Recruiting
1 Unique sponsors
2 Unique IMPs
4 Commercial trials
Drug classes (ATC)
ATC code not specified 3
B Haematology (ATC B) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
Factor Xa inhibitor (DOAC) 1 substance
Phase III: 2 Phase I (Other): 2

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

2 trials
  • Bayer AG Commercial
    ASUNDEXIAN
    2023-503793-20-00 20 countries 2023 n=5,223
    Ended
  • Bayer AG Commercial
    APIXABAN; ASUNDEXIAN
    2023-503794-38-00 22 countries 2022 n=9,578
    Ended

Phase I (Other)

2 trials
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Bayer AG Commercial 4 Phase I (Other), Phase III 0
New trials by year
2022
1
2023
1
2024
2
← All indication landscapes